Just saw AbbVie submitted Rinvoq to FDA and EMA for vitiligo treatment. Basically their JAK inhibitor is showing promise for non-segmental vitiligo cases in adults and teens. The Phase 3 Viti-Up data looks solid - hit both endpoints with 50%+ body repigmentation and 75%+ facial repigmentation improvement at week 48. Pretty significant if you think about how limited vitiligo treatment options have been historically. They already have Rinvoq approved for rheumatoid arthritis and various GI conditions, so the regulatory pathway might move faster here. Stock was up around 1% on the news back when this dropped. Curious how long the approval process will take, especially with EMA involved. This could be a game-changer for vitiligo patients if it comes through. Anyone following biotech plays on this one?